27799085|t|Atheroprotective effects of pure tocotrienol supplementation in the treatment of rabbits with experimentally induced early and established atherosclerosis
27799085|a|Atherosclerosis is the main cause of coronary artery disease -related deaths worldwide. The atheroprotective properties of pure tocotrienols (T3) in the absence of alpha-tocopherol (α-TCP) in vitamin E has not been extensively examined. To determine the atheroprotective properties of T3 in early and established atherosclerosis rabbits. Thirty New Zealand white rabbits were divided into two groups, B1 and B2 which represent early [fed 1% high cholesterol diet (HCD) for 2 weeks] and established (fed 1% HCD for 8 weeks) atherosclerosis. Each group was subdivided into three intervention arms: 1) T3 -4 mg/kg, 2) T3 -15 mg/kg and 3) vehicle without T3 (T3 negative) for 8 weeks. Serial fasting blood samples were obtained for lipid profile, and whole lengths of aorta were used to determine tissue markers of endothelial activation, inflammation and plaque stability. In B1, atherosclerotic lesion in T3 -4 mg/kg group was significantly reduced (p=0.008), while aortic tissue expression of vascular cellular adhesion molecule 1 (VCAM-1), interleukin-6 (IL-6) and matrix metalloproteinase (MMP-12) was reduced in T3 -4 mg/kg compared to T3 -negative rabbits group (0.2±0.1 vs. 28.5±3.1%; 3.0±1.6 vs. 14.0±1.7%; and 5.2±2.2 vs. 27.7±0.8%, respectively, p<0.05). T3 -15 mg/kg group showed reduction in VCAM-1, E-selectin, IL-6 and MMP-12 (3.9±1.9 vs. 28.5±3.1%; 10.3±0.5 vs. 59.8±8.5%; 2.6±1.7 vs. 14.0±1.7%; and 16.2±3.2 vs. 27.7 0.8%, respectively, p<0.05). In B2, T3 -4 mg/kg group reduced aortic tissue expression of intercellular adhesion molecule 1 (ICAM-1), E-selectin, IL-6, MMP-12 and MMP-9 compared to T3 -negative rabbits group (29.9±2.4 vs. 55.3±1.3%; 26.7±1.5 vs. 60.5±7.6%; 15.7±0.7 vs. 27.7±4.8%; 34.8±2.7 vs. 46.5±3.4%; and 25.89±3.9 vs. 45.9±1.7%, respectively, p<0.05). T3 -15 mg/kg group showed reduced VCAM-1, ICAM-1, E-selectin, IL-6, MMP-12 and MMP-9 (20.5±3.3 vs. 35.6±2.5%; 24.9±1.3 vs. 55.3±1.3%; 29.9±6.7 vs. 60.5±7.6; 11.3±2.2 vs. 27.7±4.8%; 23.0±1.7 vs. 46.5±3.4%; and 17.6±1.9 vs. 45.9±1.7%, respectively, p<0.05. These findings suggest the possible atheroprotective role T3 plays as an adjunct supplementation to standard treatment in the prevention of CAD.
27799085	33	44	tocotrienol	T103	UMLS:C0949647
27799085	45	60	supplementation	T058	UMLS:C0087111
27799085	68	77	treatment	T058	UMLS:C0087111
27799085	81	88	rabbits	T204	UMLS:C0324547
27799085	139	154	atherosclerosis	T038	UMLS:C0004153
27799085	155	170	Atherosclerosis	T038	UMLS:C0004153
27799085	192	215	coronary artery disease	T038	UMLS:C0010068
27799085	225	231	deaths	T033	UMLS:C1306577
27799085	283	295	tocotrienols	T103	UMLS:C0949647
27799085	297	299	T3	T103	UMLS:C0949647
27799085	319	335	alpha-tocopherol	T103	UMLS:C0969677
27799085	337	342	α-TCP	T103	UMLS:C0969677
27799085	347	356	vitamin E	T103	UMLS:C0042874
27799085	440	442	T3	T103	UMLS:C0949647
27799085	468	483	atherosclerosis	T038	UMLS:C0004153
27799085	484	491	rabbits	T204	UMLS:C0324547
27799085	500	525	New Zealand white rabbits	T204	UMLS:C0324547
27799085	596	617	high cholesterol diet	T168	UMLS:C0012155
27799085	619	622	HCD	T168	UMLS:C0012155
27799085	661	664	HCD	T168	UMLS:C0012155
27799085	678	693	atherosclerosis	T038	UMLS:C0004153
27799085	754	756	T3	T103	UMLS:C0949647
27799085	770	772	T3	T103	UMLS:C0949647
27799085	790	797	vehicle	T204	UMLS:C0324547
27799085	806	808	T3	T103	UMLS:C0949647
27799085	810	812	T3	T103	UMLS:C0949647
27799085	843	850	fasting	T033	UMLS:C0015663
27799085	851	864	blood samples	T031	UMLS:C0178913
27799085	883	896	lipid profile	T058	UMLS:C0430044
27799085	919	924	aorta	T017	UMLS:C0003483
27799085	948	954	tissue	T017	UMLS:C0040300
27799085	955	962	markers	T201	UMLS:C0005516
27799085	966	988	endothelial activation	T038	UMLS:C1155002
27799085	990	1002	inflammation	T038	UMLS:C0021368
27799085	1007	1013	plaque	T033	UMLS:C0332461
27799085	1032	1047	atherosclerotic	T038	UMLS:C0004153
27799085	1048	1054	lesion	T033	UMLS:C0221198
27799085	1058	1060	T3	T103	UMLS:C0949647
27799085	1119	1125	aortic	T017	UMLS:C0003483
27799085	1126	1132	tissue	T017	UMLS:C0040300
27799085	1133	1143	expression	T038	UMLS:C1171362
27799085	1147	1184	vascular cellular adhesion molecule 1	T103	UMLS:C0078056
27799085	1186	1192	VCAM-1	T103	UMLS:C0078056
27799085	1195	1208	interleukin-6	T103	UMLS:C0021760
27799085	1210	1214	IL-6	T103	UMLS:C0021760
27799085	1220	1244	matrix metalloproteinase	T103	UMLS:C0968475
27799085	1246	1252	MMP-12	T103	UMLS:C0968475
27799085	1269	1271	T3	T103	UMLS:C0949647
27799085	1293	1295	T3	T103	UMLS:C0949647
27799085	1306	1313	rabbits	T204	UMLS:C0324547
27799085	1417	1419	T3	T103	UMLS:C0949647
27799085	1456	1462	VCAM-1	T103	UMLS:C0078056
27799085	1464	1474	E-selectin	T103	UMLS:C0115305
27799085	1476	1480	IL-6	T103	UMLS:C0021760
27799085	1485	1491	MMP-12	T103	UMLS:C0968475
27799085	1621	1623	T3	T103	UMLS:C0949647
27799085	1647	1653	aortic	T017	UMLS:C0003483
27799085	1654	1660	tissue	T017	UMLS:C0040300
27799085	1661	1671	expression	T038	UMLS:C1171362
27799085	1675	1708	intercellular adhesion molecule 1	T103	UMLS:C0063695
27799085	1710	1716	ICAM-1	T103	UMLS:C0063695
27799085	1719	1729	E-selectin	T103	UMLS:C0115305
27799085	1731	1735	IL-6	T103	UMLS:C0021760
27799085	1737	1743	MMP-12	T103	UMLS:C0968475
27799085	1748	1753	MMP-9	T103	UMLS:C0165519
27799085	1766	1768	T3	T103	UMLS:C0949647
27799085	1779	1786	rabbits	T204	UMLS:C0324547
27799085	1942	1944	T3	T103	UMLS:C0949647
27799085	1976	1982	VCAM-1	T103	UMLS:C0078056
27799085	1984	1990	ICAM-1	T103	UMLS:C0063695
27799085	2004	2008	IL-6	T103	UMLS:C0021760
27799085	2010	2016	MMP-12	T103	UMLS:C0968475
27799085	2021	2026	MMP-9	T103	UMLS:C0165519
27799085	2203	2211	findings	T033	UMLS:C0243095
27799085	2255	2257	T3	T103	UMLS:C0949647
27799085	2270	2293	adjunct supplementation	T058	UMLS:C0677850
27799085	2306	2315	treatment	T058	UMLS:C0087111
27799085	2337	2340	CAD	T038	UMLS:C0010068